Cresco Labs Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Cresco Labs yıllık ortalama 19.3% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 19.2% annual. Gelirler azalıyor .
Anahtar bilgiler
19.30%
Kazanç büyüme oranı
26.31%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 23.06% |
| Gelir büyüme oranı | -2.30% |
| Özkaynak getirisi | -58.07% |
| Net Marj | -20.90% |
| Sonraki Kazanç Güncellemesi | 06 Aug 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
Anlatı Güncellemesi • Jul 02
CL: Expanded Ohio Dispensary Footprint Will Support Future Upside Potential
Analysts have adjusted their CA$ fair value estimate for Cresco Labs from about CA$2.42 to roughly CA$2.72, reflecting updated views on its revenue outlook, profit margins, discount rate and future P/E assumptions. What’s in the News for Cresco Labs Cresco Labs opened Sunnyside Aberdeen in Aberdeen, Ohio, the company’s second Ohio dispensary opening in the past month.
Anlatı Güncellemesi • Jun 18
CL: Texas License And Expanded Ohio Stores Will Support Upside Skewed Profile
Analysts have nudged their fair value estimate for Cresco Labs stock from about CA$2.25 to roughly CA$2.35 per share, reflecting updated assumptions around discount rates, revenue growth, and future P/E expectations. What’s in the News for Cresco Labs Cresco Labs opened Sunnyside Aberdeen in Aberdeen, Ohio, its second Ohio dispensary opening in the past month, bringing its footprint to eight locations in the state and 74 nationally.Anlatı Güncellemesi • Jun 04
CL: Expanded Footprint And Texas License Will Support A More Upside Skewed Profile
Analysts trimmed their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions around revenue growth, discount rate, profit margin and future P/E that together support a slightly lower fair value estimate. What's in the News Cresco Labs opened Sunnyside Aberdeen in Aberdeen, Ohio, its second new Ohio dispensary in the past month, bringing the footprint to eight locations in the state and 74 nationally.Anlatı Güncellemesi • May 05
CL: Lower P/E Expectations Will Support A More Upside Skewed Profile
Analysts now see Cresco Labs trading closer to CA$2.25 rather than CA$2.50, reflecting updated views on fair value, growth assumptions, profitability, discount rate and future P/E expectations. Analyst Commentary Bearish analysts have adjusted their view on Cresco Labs, with a lower price target of CA$2.25 compared with the earlier CA$2.50 level.Anlatı Güncellemesi • Apr 20
CL: Discount-Adjusted Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have trimmed their CA$ price target on Cresco Labs from CA$2.50 to CA$2.25, reflecting updated expectations for the discount rate, profit margin and future P/E assumptions. Analyst Commentary The revised CA$2.25 price target signals that analysts are updating their view of Cresco Labs as they refresh discount rate, margin and P/E assumptions, rather than completely changing their stance on the business.Anlatı Güncellemesi • Apr 05
CL: Revised Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have reduced their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions regarding fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts have adjusted their view on Cresco Labs by trimming the price target to CA$2.25 from CA$2.50 while maintaining a Speculative Buy stance, which reflects both perceived upside potential and meaningful execution risk.Anlatı Güncellemesi • Mar 22
CL: Lower P/E Assumptions Will Support A More Upside-Skewed Outlook
Analysts now see Cresco Labs' fair value as aligning with a trimmed CA$2.25 price target, down from CA$2.50. This reflects updated views on growth, margins and a lower future P/E assumption.Anlatı Güncellemesi • Mar 07
CL: Higher Future P/E Assumptions Will Shape A More Upside-Skewed Outlook
Analysts have lowered their price target on Cresco Labs to CA$2.25 from CA$2.50, reflecting updated views on revenue growth, profit margins, and a much higher assumed future P/E multiple. Analyst Commentary Bearish analysts are signaling a more cautious stance on Cresco Labs by trimming their price target to CA$2.25 from CA$2.50, even while still seeing speculative upside potential.Anlatı Güncellemesi • Feb 21
CL: Expanded Retail Footprint And Flexible Equity Program Will Support A More Optimistic Outlook
Analysts have revised their price target on Cresco Labs to CA$16.91 from CA$18.36, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. What's in the News Cresco Labs filed a follow on equity offering for up to CA$140 million of Subordinate Voting Shares through an at the market program, giving the company flexibility to raise capital over time (Key Developments).Analiz Makalesi • Feb 12
Cresco Labs Inc. (CSE:CL) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
Cresco Labs Inc. ( CSE:CL ) shares have had a horrible month, losing 29% after a relatively good period beforehand. The...Anlatı Güncellemesi • Feb 06
CL: Expanded Retail And EU Entry Will Support A More Optimistic Outlook
Analysts have lifted their price target on Cresco Labs to US$1.94 from US$1.51, citing revised assumptions around revenue growth, profit margins, discount rate, and a lower future P/E multiple as key drivers of the change. What's in the News Cresco Labs filed a follow on equity offering of up to C$140 million in subordinate voting shares through an at the market program, adding flexibility to raise capital as needed (Key Developments).Anlatı Güncellemesi • Jan 23
CL: New German Entry Will Support Future Upside
Analysts have nudged their price target for Cresco Labs higher, now implying fair value of about $2.40 per share versus roughly $2.36 previously. The change reflects updated views on revenue growth, profit margins and future P/E assumptions.Anlatı Güncellemesi • Jan 09
CL: German Entry And Higher Margins Will Support Future Upside
Analysts have raised their price target for Cresco Labs from US$2.30 to about US$2.36, reflecting updated views on the company’s profit margin outlook and a lower assumed future P/E multiple. What's in the News Cresco Labs launched Cresco branded flower in Germany, marking its first commercial entry into the European Union and extending its growth plans beyond the U.S. cannabis market (Key Developments).Anlatı Güncellemesi • Dec 15
CL: Expanded Retail And European Entry Will Support Stronger Profitability
Analysts have modestly raised their price target on Cresco Labs to reflect an updated fair value estimate of approximately 2.30 dollars, up from about 2.16 dollars previously, citing expectations for stronger revenue growth, improved profit margins, a slightly lower discount rate, and a more reasonable future earnings multiple. What's in the News Entered the European Union with the launch of Cresco branded flower in Germany, using the market as a testbed for broader international expansion beyond U.S. cannabis (Key Developments).Analiz Makalesi • Nov 26
Cresco Labs Inc. (CSE:CL) Not Doing Enough For Some Investors As Its Shares Slump 37%
Unfortunately for some shareholders, the Cresco Labs Inc. ( CSE:CL ) share price has dived 37% in the last thirty days...Analiz Makalesi • Nov 08
Here's Why Cresco Labs (CSE:CL) Is Weighed Down By Its Debt Load
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analiz Makalesi • Oct 12
Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 35% But Growth Is Lacking
Despite an already strong run, Cresco Labs Inc. ( CSE:CL ) shares have been powering on, with a gain of 35% in the last...Analiz Makalesi • Sep 06
Is Cresco Labs Inc. (CSE:CL) Trading At A 49% Discount?
Key Insights Cresco Labs' estimated fair value is CA$3.23 based on 2 Stage Free Cash Flow to Equity Current share price...Analiz Makalesi • Jul 31
Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 27% But Growth Is Lacking
Cresco Labs Inc. ( CSE:CL ) shareholders are no doubt pleased to see that the share price has bounced 27% in the last...Analiz Makalesi • Jul 23
Cresco Labs (CSE:CL) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analiz Makalesi • Jun 15
Cresco Labs Inc.'s (CSE:CL) 30% Share Price Plunge Could Signal Some Risk
The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 30...Analiz Makalesi • May 01
Cresco Labs Inc.'s (CSE:CL) Shares Climb 31% But Its Business Is Yet to Catch Up
Cresco Labs Inc. ( CSE:CL ) shareholders would be excited to see that the share price has had a great month, posting a...
Yeni Anlatı • Mar 29
Expanding Production In Illinois, Pennsylvania And Kentucky Will Meet Demand
Expansion in Illinois and Pennsylvania and entry into Kentucky's market aim to boost revenue growth and market share.Analiz Makalesi • Mar 07
Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 27%
The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 27...Analiz Makalesi • Jan 31
Is Cresco Labs (CSE:CL) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analiz Makalesi • Dec 14
Cresco Labs Inc. (CSE:CL) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
To the annoyance of some shareholders, Cresco Labs Inc. ( CSE:CL ) shares are down a considerable 28% in the last...Analiz Makalesi • Oct 24
Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely
It's not a stretch to say that Cresco Labs Inc.'s ( CSE:CL ) price-to-sales (or "P/S") ratio of 0.8x right now seems...Analiz Makalesi • Aug 11
Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Investors in Cresco Labs Inc. ( CSE:CL ) had a good week, as its shares rose 3.4% to close at CA$2.15 following the...Analiz Makalesi • Jul 17
Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?
Key Insights Cresco Labs' estimated fair value is CA$3.60 based on 2 Stage Free Cash Flow to Equity Current share price...Analiz Makalesi • Jun 19
Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Jun 19
Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 26...Analiz Makalesi • Mar 16
Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41
The investors in Cresco Labs Inc. 's ( CSE:CL ) will be rubbing their hands together with glee today, after the share...Analiz Makalesi • Mar 03
Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%
Cresco Labs Inc. ( CSE:CL ) shareholders won't be pleased to see that the share price has had a very rough month...Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Cresco Labs nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Mar 26 | 641 | -134 | 227 | 0 |
| 31 Dec 25 | 656 | -135 | 227 | 0 |
| 30 Sep 25 | 673 | -52 | 229 | 0 |
| 30 Jun 25 | 688 | -46 | 234 | 0 |
| 31 Mar 25 | 708 | -84 | 238 | 0 |
| 31 Dec 24 | 724 | -74 | 233 | 0 |
| 30 Sep 24 | 733 | -67 | 227 | 0 |
| 30 Jun 24 | 741 | -172 | 232 | 0 |
| 31 Mar 24 | 747 | -155 | 239 | 0 |
| 31 Dec 23 | 756 | -176 | 257 | 0 |
| 30 Sep 23 | 767 | -339 | 284 | 0 |
| 30 Jun 23 | 786 | -234 | 295 | 0 |
| 31 Mar 23 | 806 | -211 | 307 | 0 |
| 31 Dec 22 | 825 | -212 | 310 | 0 |
| 30 Sep 22 | 842 | -65 | 295 | 0 |
| 30 Jun 22 | 848 | -326 | 295 | 0 |
| 31 Mar 22 | 841 | -318 | 292 | 0 |
| 31 Dec 21 | 806 | -320 | 276 | 0 |
| 30 Sep 21 | 750 | -360 | 276 | 0 |
| 30 Jun 21 | 687 | -73 | 246 | 0 |
| 31 Mar 21 | 573 | -105 | 215 | 0 |
| 31 Dec 20 | 463 | -102 | 199 | 0 |
| 30 Sep 20 | 345 | -76 | 163 | 0 |
| 30 Jun 20 | 231 | -98 | 145 | 0 |
| 31 Mar 20 | 168 | -64 | 119 | 0 |
| 31 Dec 19 | 124 | -43 | 92 | 0 |
| 30 Sep 19 | 101 | -20 | 77 | 0 |
| 30 Jun 19 | 78 | -14 | 63 | 0 |
| 31 Mar 19 | 57 | -12 | 46 | 0 |
| 31 Dec 18 | 41 | -2 | 31 | 0 |
| 30 Sep 18 | 28 | 0 | 19 | 0 |
| 30 Jun 18 | 19 | 1 | 9 | 0 |
| 31 Mar 18 | 13 | 1 | 7 | 0 |
| 31 Dec 17 | 10 | -3 | 5 | 0 |
| 31 Dec 16 | 3 | -8 | 4 | 0 |
Kaliteli Kazançlar: CL şu anda kârlı değil.
Büyüyen Kar Marjı: CL şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: CL kârlı değildir, ancak son 5 yılda zararlarını yılda 19.3% oranında azaltmıştır.
Büyüme Hızlandırma: CL 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: CL kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 96.7% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: CL hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -58.07% ) sahiptir.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/26 04:29 |
| Gün Sonu Hisse Fiyatı | 2026/07/24 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Cresco Labs Inc. 11 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Luke Hannan | Canaccord Genuity |